Progressive Care Announces 2020 Annual and Quarterly Financial and Operational Performance Highlights

Rhea-AI Summary

Progressive Care Inc. (OTCQB:RXMD) reported its audited financial performance for 2020, showcasing significant achievements despite challenges. Q4 2020 consolidated revenue reached $10.1 million, a 1% increase from Q4 2019, while EBITDA surged 104% to $667k. For the fiscal year, total revenue climbed 22% to $40.3 million, with a remarkable 300% rise in 340B revenue. The company ended 2020 with net cash of $2.1 million, a substantial improvement over the previous year. Leaders highlighted proactive strategies in response to rising PBM fees and growth in COVID-19 testing services, underlining a strong foundation for 2021.

Positive

• Q4 2020 consolidated revenue was $10.1 million, a 1% increase year-over-year.
• Fiscal 2020 consolidated revenue rose 22% to $40.3 million.
• 340B revenue increased over 300% to approximately $2.8 million for FY 2020.
• EBITDA for Q4 2020 grew 104% to $667k compared to Q4 2019.
• Net cash improved to $2.1 million from $816k in 2019.
• RXMD shares rose more than 300% during 2020.

Negative

• DIR and other PBM fees increased over 285% to $1.4 million in 2020, negatively impacting profitability.

MIAMI, FL, April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. (OTCQB:RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to announce the filing of the Company’s audited 2020 financial performance data, closing the books on a momentous year that featured strong execution in the face of historic obstacles, the establishment of new executive leadership, the successful establishment of new scalable strategies, and tremendous gains in net cash, EBITDA, and topline results, which have helped to drive shareholder value so far in 2021.

Read more

Financial Highlights for Quarter Ended Dec 31, 2020

• Consolidated Revenue for the quarter was $10.1 million, representing an increase of 1% compared to Q4 2019.
• Prescriptions filled during Q4 totaled approximately 134,000, representing an increase of 1% compared to Q4 2019.
• 340B revenue was approximately $879k, representing a sharp increase of 200% compared to Q4 2019.
• EBITDA increased 104% to $667k in Q4 2020 when compared to the same period in 2019.

Financial Highlights for Fiscal Year Ended Dec 31, 2020

• Consolidated Revenue was $40.3 million, representing an increase of 22% compared to fiscal 2019.
• Prescriptions filled was approximately 530,000, representing an increase of 16% compared to fiscal 2019.
• 340B revenue was approximately $2.8 million, representing a sharp increase of over 300% compared to fiscal 2019.
• COVID testing revenue was approximately $600K, most of which was earned in Q4 2020.
• Realized positive EBITDA of $7K when compared to $479K negative EBITDA in 2019.
• Cash provided by operations was $1.1 million in 2020, compared to $600K cash used in 2019.
• Net Cash balances as of Dec 31, 2020 was $2.1 million vs $816K compared to 2019.

Operational Highlights for the Year Ended Dec 31, 2020

• Fundamental changes in management: Alan Jay Weisberg named CEO; Cecile Munnik named CFO.
• Finished year with 5-Star rating earning Humana bonus of approximately $904K.
• Paid off note for the building of $300K plus interest.
• Generated $700K in third-party administration fees through services provided to 340B Covered Entities.
• Strong execution and pro-growth strategic path resulted in shareholder value, with RXMD shares rising more than 300% during 2020.

“We confronted adversity successfully in 2020, and we have hit the ground running in 2021,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “In addition to the pandemic and the associated challenges, we adjusted well to a headwind in the form of higher DIR and PBM fees. Over the past year, we have also expanded operations and our overall strategic path to position for a future that leans more heavily on scalable growth opportunities, including data management, telehealth and virtual healthcare services, and technology applications that leverage our built-in market advantages.”

EBITDA and Net Cash Improvements. EBITDA increased by approximately $500K for the year ended December 31, 2020 when compared to the same period in 2019. This increase is primarily attributable to increased interest expenses offset by a favorable change in the fair value of embedded derivative exposure and funding received to cover certain payroll expenses during the pandemic.

Net cash provided by operating activities totaled $1.1 million for the year ended December 31, 2020 compared to net cash used in operating activities of $600K for the year ended December 31, 2019. Operational cash flow was positively impacted by the increase in accounts payable and accrued liabilities for the year ended December 31, 2020, which was largely due to the significant increase in billing activity from 340B contracts. Net cash used in investing activities was $700K for the year ended December 31, 2020, which was attributable to equipment purchases, construction in progress at the Hallandale Beach and Orlando buildings, and leasehold improvements.

Pharmacy Fees. DIR fees and other PBM fees continued to apply significant downward pressure on profitability. DIR fees are PBM clawbacks of reimbursements based on factors that vary from plan to plan. DIR fees are often applied retroactively, which has caused a significant increase in the fees charged. During the year ended December 31, 2020, DIR and other PBM fees were $1.4 million, an increase of over 285% when compared to DIR and other PBM fees of $400K in the same period in 2019.

The increase in DIR and other PBM fees is primarily due to insurance carriers changing PBMs starting at the beginning of 2020, which has resulted in a high concentration of claims being processed by a single PBM with significantly higher DIR and other PBM fees. Management anticipates a positive shift to PBM fees due to imposed regulations on PBMs and changes in policies that can affect rates in the future. Any decrease in fees should have a positive impact on profitability.

Physical Consolidation. In December 2020, the Company completed the move of its PharmCo 901 pharmacy into its new 11,000 square foot pharmacy facility in Hallandale Beach, Florida. PharmCo 901 will continue to operate at an approximately 1,050 square foot location at the North Miami Beach, Florida location.

The consolidation of space is expected to save the Company approximately $130,000 annually in lease and associated occupancy expenses in 2021. In January 2021, we completed our move of our PharmCo 1103 Orlando location into its new 3,700 square foot location in January 2021. Management anticipates this expanded facility in Orlando to drive important performance gains, including advances in productivity, volume, and market reach due to expanded space and associated efficiencies.

Covid-19 Testing and MyVax Operations. During the third quarter of 2020, the Company launched an aggressive expansion of its COVID-19 testing service registered through the FDA under its Emergency Use Authorization (“EUA”) guidelines, featuring Polymerase Chain Reaction (“PCR”) and Antigen testing systems that produces rapid detection of the SARS-CoV-2 virus with market-leading accuracy in 15 to 45 minutes. The Company has successfully tested approximately 5,000 patients, earning a reputation as a preferred provider for in-patient and out-patient COVID-19 Rapid Testing solutions, and driving approximately $600k in related revenues for the year ended December 31, 2020.

In February 2021, the Company entered into a service agreement with EagleForce Health, LLC to integrate its proprietary telehealth platform, “myVax”. This will include a Digital Passport or Digital Wallet that is QR-coded for registration, verification, and documentation of COVID-19 vaccination and/or test results. Management anticipates this platform to be operational in the second quarter of 2021. The MyVax platform will include complete patient scheduling, telehealth, and tele-pharmacy platform services.

For more information about Progressive Care, please visit the company’s website.

Connect and stay in touch with us on social media:

Progressive Care Inc.
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS

PharmCoRx
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx

ClearMetrX
https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/

About Progressive Care:

Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

Cautionary Disclosure Regarding Forward-Looking Statements Forward-Looking Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

Public Relations Contact:
Carlos Rangel
carlosr@pharmcorx.com

FAQ

What were the key financial highlights of Progressive Care for Q4 2020?

Progressive Care reported Q4 2020 consolidated revenue of $10.1 million, a 1% increase from Q4 2019, with EBITDA increasing 104% to $667k.

How did Progressive Care perform in fiscal year 2020?

In fiscal year 2020, Progressive Care achieved a consolidated revenue of $40.3 million, up 22% from 2019, and an EBITDA of $7k, a significant improvement from a negative EBITDA of $479k in 2019.

What factors contributed to the increase in cash for Progressive Care?

The increase in cash to $2.1 million in 2020 was largely due to improved cash from operations totaling $1.1 million, compared to a cash usage of $600k in 2019.

How did PBM fees affect Progressive Care's profitability?

PBM fees, specifically DIR fees, increased over 285% to $1.4 million in 2020, placing significant downward pressure on profitability.

What is the significance of 340B revenue for Progressive Care?

340B revenue for Progressive Care saw a sharp increase over 300%, contributing approximately $2.8 million for the fiscal year 2020.